・The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window. ・The therapy reached this stage after progressing through the Day-120 and Day-180 questions ...
The EU ombudsman has asked the EMA to explain redactions to clinical study reports (CSRs) for AbbVie's ($ABBV) Humira. The EMA responded quickly to the publication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results